SCHEMBL5954469

SCHEMBL5954469

COc1ccc(N2C(=O)C(C)N(c3ccc(Oc4ccccc4)cc3)C2=S)cc1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.47
MAPT P10636 6/20 0.47
LTA4H P09960 1/20 0.46
MGLL Q99685 1/20 0.46
LMNA P02545 1/20 0.45
ALDH1A1 P00352 7/20 0.44
MAPK1 P28482 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
HSD11B1 P28845 1/20 0.43
GAA P10253 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
TSHR P16473 1/20 0.43
APOBEC3G Q9HC16 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
GFER P55789 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5955343 1.00 ABCB1 (0.47) ABCB1MAPTLTA4HMGLLLMNA
SCHEMBL5955006 0.95 MGLL (0.50) ABCB1MAPTMGLLLMNAALDH1A1
SCHEMBL5954383 0.93 MGLL (0.49) ABCB1MAPTMGLLLMNAALDH1A1
SCHEMBL5954389 0.93 MGLL (0.49) ABCB1MAPTMGLLLMNAALDH1A1
SCHEMBL5954387 0.93 MGLL (0.49) ABCB1MAPTMGLLLMNAALDH1A1
SCHEMBL5954470 0.93 MGLL (0.49) ABCB1MAPTMGLLLMNAALDH1A1
SCHEMBL5954503 0.89 LTA4H (0.45) MAPTLTA4HMGLLLMNAALDH1A1
SCHEMBL5954376 0.89 ALDH1A1 (0.46) MAPTMGLLLMNAALDH1A1TDP1
SCHEMBL5954435 0.89 CDK2 (0.44) MAPTMGLLLMNAALDH1A1MAPK1
SCHEMBL5954507 0.89 LTA4H (0.47) MAPTLTA4HMGLLALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LABORATOIRES FOURNIER S.A. (FR) 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LIPC, CYP4F2, SLC5A2 ABCB1 290/4885MAPT 4311/4885LTA4H 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.